Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

The Southwest Oncology Group conducted a randomized trial comparing lenalidomide (LEN) plus dexamethasone (DEX; n = 97) to placebo (PLC) plus DEX (n = 95) in newly diagnosed myeloma. Three 35-day induction cycles applied DEX 40 mg/day on days 1 to 4, 9 to 12, and 17 to 20 together with LEN 25 mg/day...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Zonder, Jeffrey A., Crowley, John, Hussein, Mohamad A., Bolejack, Vanessa, Moore, Dennis F., Whittenberger, Brock F., Abidi, Muneer H., Durie, Brian G. M., Barlogie, Bart
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2010
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3031379/
https://ncbi.nlm.nih.gov/pubmed/20876454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-08-303487
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak